22 February 2024FeaturesBiotechnologyJens Petry and Tom Gassmann, Squire Patton Boggs
Dispute resolution in Asian biotech joint ventures: things to consider
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.
4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.
8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.